Published in Gene Therapy Weekly, March 1st, 2007
Study 1: New research, "Improved HSV-1 amplicon packaging using virion host shutoff mutants lacking mRNAse activity," is the subject of a report. According to a study from the United States, "Given their generous transgene capacity and inherent neurotropism, herpes simplex virus (HSV-1)-based viral vectors are promising tools for gene delivery to the central nervous system. Despite their widespread pre-clinical use, vector toxicity remains a concern with regard to the use of herpes vectors in humans."
"One potential source of toxicity stems from the tegument-associated virion host...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.